These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 678104)

  • 1. Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications.
    Felix EL; Jessup JM; Cohen MH
    Arch Surg; 1978 Jul; 113(7):893-6. PubMed ID: 678104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
    McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
    Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility study of active immunotherapy in patients with solid tumors.
    Gerner RE; Moore GE
    Cancer; 1976 Jul; 38(1):131-43. PubMed ID: 779950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epilesional scarification. Preliminary report of a new approach to local immunotherapy with BCG.
    Richman SP; Mavligit GM; Wolk R; Gutterman JU; Hersh EM
    JAMA; 1975 Dec; 234(12):1233-5. PubMed ID: 1242748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
    Korting HC; Strasser S; Konz B
    Hautarzt; 1988 Mar; 39(3):170-3. PubMed ID: 3378889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulomas in melanoma patients treated with BCG immunotherapy.
    Hatzitheofilou C; Obenchain DF; Porter DD; Morton DL
    Cancer; 1982 Jan; 49(1):55-60. PubMed ID: 7053820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
    de la Monte SM; Hutchins GM
    Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative.
    Lokich JJ; Garnick MB; Legg M
    Oncology; 1979; 36(5):236-41. PubMed ID: 481845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and immunologic studies of disseminated BCG infection.
    Rosenberg SA; Seipp C; Sears HF
    Cancer; 1978 May; 41(5):1771-80. PubMed ID: 647627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
    Mastrangelo MJ; Bellet RE; Berkelhammer J; Clark WH
    Cancer; 1975 Oct; 36(4):1305-8. PubMed ID: 1175129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pott's disease following BCG therapy of melanoma.
    Strausser JL; Quindlen EA
    Cancer; 1981 Sep; 48(5):1154-6. PubMed ID: 7272949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycotic abdominal aortic aneurysm induced by immunotherapy with bacille Calmette-Guérin vaccine for malignancy.
    Woods JM; Schellack J; Stewart MT; Murray DR; Schwartzman SW
    J Vasc Surg; 1988 Jun; 7(6):808-10. PubMed ID: 3286902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaphylactic reaction to intralesional B.C.G.
    Proctor JW; Zidar B; Pomerantz M; Yamamura Y; Eng CP; Woodside D
    Lancet; 1978 Jul; 2(8081):162. PubMed ID: 78369
    [No Abstract]   [Full Text] [Related]  

  • 20. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma.
    Nathanson L; Schoenfeld D; Regelson W; Colsky J; Mittelman A
    Cancer; 1979 May; 43(5):1630-5. PubMed ID: 376098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.